Results 131 to 140 of about 19,040 (169)

Comparative Analysis of Anticoagulation Stability in Critically Ill Patients Receiving Argatroban for Suspected or Confirmed Heparin-Induced Thrombocytopenia Compared with Unfractionated Heparin: A Retrospective Cohort Study. [PDF]

Hematol Rep
Khan I, Lamarche E, Kovacs B, Hendin A, Pan A, Richler C, Landry C, Morin S, Derouiche K, Thabet P.   +9 more
europepmc   +1 more source

Utilizing Argatroban for Neuroendovascular Therapy in Heparin-Induced Thrombocytopenia: A Case Report and Technical Review. [PDF]

J Neuroendovasc Ther
Eguchi H, Ishiguro T, Omura Y, Takano Y, Arai T, Momozaki N, Karagiozov K, Nishitani M, Sakaguchi M, Suzuki M, Kawamata T.   +10 more
europepmc   +1 more source

Destabilization of PF4-antigenic complexes in heparin-induced thrombocytopenia.

Blood
Rauova L, Bdeir K, Rux AH, Kalathottukaren MT, Oberg J, La CC, Lim DTE, Hayes V, Koma GT, Sarkar A, Poncz M, Kizhakkedathu JN, Cines DB.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Heparin-Induced Thrombocytopenia

Annual Review of Medicine, 2010
SummaryHeparin-induced thrombocytopenia (HIT), typically occurring in the second week of heparin therapy, is an antibody-mediated adverse drug reaction associated with increased thrombotic risk. The most important antigens are located on platelet factor 4 (PF4)/heparin complexes.
Gowthami M Arepally
exaly   +5 more sources

Heparin-induced thrombocytopenia

Clinical Toxicology, 2014
Abstract A summary of heparin-induced thrombocytopenia (HIT) is presented. HIT is an adverse drug reaction characterized by thrombocytopenia and a high risk for venous or arterial thrombosis. The frequency of HIT ranges from 1 to 5% of patients receiving heparin with exact frequencies ranging between specific agents. Interestingly, this immune-mediated
exaly   +3 more sources

Heparin-induced thrombocytopenia

Journal of Vascular Nursing, 1995
Heparin is one of the most frequently prescribed medications in the United States with more than 1 trillion units being used each year. However, some patients who receive heparin may have development of a rare but severe complication called heparin-induced thrombocytopenia, which is associated with significant morbidity and mortality rates.
D A, Borkowski, R W, Force
openaire   +4 more sources

HEPARIN‐INDUCED THROMBOCYTOPENIA

BJU International, 2007
Each year, 25% of all hospitalized patients are affected by venous thromboembolism, a disease comprising deep vein thrombosis and pulmonary embolism, that is responsible for up to 10% of all inpatient deaths (Alikhan, Peters, Wilmott, Cohen, 2004). Used in both the treatment and the prevention of venous thromboembolism, heparin is administered to more ...
openaire   +4 more sources

Heparin-induced thrombocytopenia

Expert Review of Cardiovascular Therapy, 2004
Heparin is widely used for the prevention and treatment of thrombotic and particularly cardiovascular disorders. Unfortunately, 0.5 to 3.0% of patients given heparin develop an immune reaction, commonly termed Type II heparin-induced thrombocytopenia (HIT).
Beng H, Chong, James J H, Chong
openaire   +4 more sources

Heparin-Induced Thrombocytopenia

Australian and New Zealand Journal of Medicine, 1988
Abstract:Thrombocytopenia is a common adverse effect of heparin therapy. Two types of heparinlinduced thrombocytopenia (HIT) are observed clinically ‐ an early onset mild thrombocytopenia (Type I) in which the patients remain asymptomatic and a delayed onset severe thrombocytopenia (Type II).
openaire   +5 more sources